Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
With a market cap of 30.92B, Biogen(BIIB) trades at $213.37. The stock has a price-to-earnings ratio of 22.42.
On 2026-07-30, Biogen(BIIB) stock opened at $210.62, reached a high of —, and a low of —.
Biogen(BIIB) shares are trading with a volume of 0, against a daily average of 1.21M.
In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $124.56.
In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $124.56.
BIIB News
Canaccord raised the firm’s price target on Biogen (BIIB) to $248 from $245 and keeps a Buy rating on the shares. The firm noted they are pleased by yet another...
Biogen Inc. ((BIIB)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing tools with Tip...
Key Points It handily beat analyst estimates on both the top and bottom lines. Investors didn't even mind a cut in adjusted net income guidance. 10 stocks we...
Analyst ratings
62%
of 37 ratingsMore BIIB News
Revenue Tops Expectations On Growth Across Key Products The Alzheimer’s drug maker reported revenues of $2.736 billion, beating the consensus of $2.458 billion...
Biogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers' 7/14/2026 Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowe...
Ami Fadia, an analyst from Needham, maintained the Buy rating on Biogen. The associated price target remains the same with $256.00. Unlock powerful investing t...
Advertisement Biogen earnings event and why it matters for shareholders Biogen (BIIB) has just reported second quarter 2026 earnings, giving investors fresh d...
Biogen BIIB reported second-quarter 2026 adjusted earnings per share (EPS) of $3.60, which significantly beat the Zacks Consensus Estimate of $3.04 per share. E...
Biogen Inc. (BIIB) came out with quarterly earnings of $5.28 per share, beating the Zacks Consensus Estimate of $4 per share. This compares to earnings of $4.02...
Reports Q2 revenue $2.736B, consensus $2.46B. “This quarter is a reflection of the significant progress Biogen (BIIB) has made repositioning the company for lon...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.